Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04840914 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction
A Phase 1 study of Chronic Heart Failure With Reduced Ejection Fraction, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 7
- Study locations
NCT04840914: Completed Phase 1 study of Chronic Heart Failure With Reduced Ejection Fraction, sponsored by Eli Lilly and Company.
NCT04840914 is a Phase 1 study of Chronic Heart Failure With Reduced Ejection Fraction that has completed, run by Eli Lilly and Company. The registered enrollment target is 44 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04840914, a Phase 1 study of Chronic Heart Failure With Reduced Ejection Fraction, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 7
- Study locations
Study Summary
The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to check concentrations of LY3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (HFrEF). The study will last up to 3 months and may include 5 visits.
Primary Outcome
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3461767
Study Locations (7)
Michigan
- Henry Ford Hospital - Detroit
Missouri
- Washington University - St Louis
North Carolina
- University of North Carolina, Division of Cardiology - Chapel Hill
Ibaraki
- Tsuchiura Kyodo Hospital - Tsuchiura
Kanagawa
- Kanagawa Prefectural Hospital Organization Kanagawa Cardiovascular and Respiratory Center - Kanazawa Ward,Yokohama
Osaka
- National Cerebral and Cardiovascular Center - Suita-shi
Tokyo
- The University of Tokyo Hospital - Bunkyo-ku
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2024-05-09 |
| Phase | Phase 1 |
What the finished NCT04840914 record still lists
NCT04840914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Chronic Heart Failure With Reduced Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04840914 lists 7 locations in 7 states (Michigan, Missouri, North Carolina).
Frequently Asked Questions
What is clinical trial NCT04840914 about?
NCT04840914 is a clinical study titled "A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction". The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to ch...
What is the current status of trial NCT04840914?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2021-06-01. Estimated completion is 2024-05-09.
What conditions does trial NCT04840914 study?
This clinical trial studies the following conditions: Chronic Heart Failure With Reduced Ejection Fraction.
What interventions are being tested in trial NCT04840914?
The interventions under investigation include: Placebo (DRUG), LY3461767 (DRUG).
Who is sponsoring clinical trial NCT04840914?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04840914 being conducted?
This trial has 7 study locations across Michigan, Missouri, North Carolina, Ibaraki, Kanagawa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04840914's enrollment target sits among peer trials
44 1086th of 2000 higher than 901 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI